Clinical Trials Directory

Trials / Completed

CompletedNCT00550745

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
11,999 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
60 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.

Conditions

Interventions

TypeNameDescription
BIOLOGICALZoster Vaccine, Livesingle 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
BIOLOGICALComparator: placebosingle 0.65 mL Placebo injection. 6 month treatment period.

Timeline

Start date
2007-09-01
Primary completion
2009-01-01
Completion
2009-01-01
First posted
2007-10-30
Last updated
2017-04-12
Results posted
2010-02-02

Source: ClinicalTrials.gov record NCT00550745. Inclusion in this directory is not an endorsement.